Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineagesSARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 및 BA.3 하위 계통의 항체 회피Article Published on 2022-08-102022-09-11 Journal: Cell Host & Microbe [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibody Antibody therapeutics antigenic approved BA.1 BA.1.1 BA.2 BA.3 BBIBP-CorV booster comparison dominant dose Efficacy highlighting homologous or heterologous IMPROVE inactivated individual lineages mAb mAbs monoclonal antibody MOST neutralization neutralization activity neutralization titer neutralization titers Neutralizing activity omicron profile pseudovirus reported SARS-CoV-2 sera side spike mutations Vaccine variant [DOI] 10.1016/j.chom.2022.05.001 PMC 바로가기 [Article Type] Article
Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variantsSARS-CoV-2 Alpha, Beta, Gamma, Delta 및 Kappa 변이체에 대한 BNT162b2 백신을 완전히 접종한 개인의 혈청/IgG 제제 중화 활성Article Published on 2022-08-082022-09-11 Journal: Scientific Reports [Category] SARS, 변종, 진단, 치료제, [키워드] (alpha administration Alpha antiviral activity approach Beta BNT162b2 BNT162b2 vaccine caused change COVID-19 pandemic Delta delta variant Effectiveness examined fraction Gamma General Hospital IgG individual Influenza influenza vaccines Japan Kumamoto long-lasting Moderation mRNA mRNA-based vaccine mutable Neutralizing activity of BNT162b2 pandemic Pathogens Prospective Study purified reduced reduction respond SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant sera vaccinated individual Vaccine variant variants wild-type SARS-CoV-2 Wuhan [DOI] 10.1038/s41598-022-17071-9 PMC 바로가기 [Article Type] Article
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariantsArticle Published on 2022-08-082022-10-06 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acting acute respiratory syndrome Administered administration antibody approved B.1.1.529 breadth cell line cGMP characterized coronavirus COVID-19 CRIPT DARPA defined diagnosed domains Emergency use FDA H2L2 mice Harbor human clinical trials human IgG1 intranasal intranasally intravenous intravenously K18-hACE2 transgenic mice LALA limit lineages Live virus lung titer NAb neutralization assays Neutralizing Neutralizing activity neutralizing antibody omicron Omicron BA.1 Omicron BA.1.1 Omicron BA.2 Pre-clinical research provided pseudotype quantitation reduced required retained SARS-CoV-2 SARS-CoV-2 neutralizing antibody SARS-CoV-2 spike subset tested therapeutic Therapies treat vaccination variant variants of concern virus weight loss [DOI] 10.1016/j.medj.2022.08.002 PMC 바로가기 [Article Type] Article
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variantmRNA 부스터 백신 접종은 SARS-CoV-2 오미크론 변이체로부터 나이든 마우스를 보호합니다Article Published on 2022-08-062022-09-11 Journal: Communications Biology [Category] SARS, 변종, 진단, [키워드] Adults Analysis benefit BNT162b2 booster booster dose booster vaccination cell-mediated response Cell-mediated responses Effect Efficacy elicit ENhance evade evaluate Evidence evidence of humoral Immunity immunization Lung infection mice mRNA mRNA BNT162b2 mRNA vaccine murine Neutralizing activity Neutralizing antibodies neutralizing antibody Older Older adults older population omicron PROTECT provide provided Recognition regimen risk SARS-CoV-2 SARS-CoV-2 variants severe disease sterilizing immunity the SARS-CoV-2 Vaccine Vaccine-induced immunity variant variants while [DOI] 10.1038/s42003-022-03765-3 PMC 바로가기 [Article Type] Article
Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2전신 자가면역 근병증: SARS-CoV-2에 대한 비활성화된 바이러스 백신의 전향적 4상 대조 시험Clinical Trial Published on 2022-08-032022-09-12 Journal: Rheumatology (Oxford, England) [Category] SARS, 임상, 진단, [키워드] 95%CI adverse event age All participant anti-SARS-CoV-2 anti-SARS-CoV-2 vaccine Autoimmune baseline Comorbidity comparable control group Controlled trial CoronaVac COVID-19 CTRL disease disease status dose drug evaluate Frequency geometric mean titre GMT HIV/AIDS IgG immune response immunogenicity immunogenicity analysis Immunosuppression in both group inactivated interquartile range IQR less median Mild moderate Myopathy myositis Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody parameters participant Patient positive pre-vaccination protocol reduced RT-PCR S1/S2 Safe Safety SAM SARS-CoV-2 SARS-CoV-2 vaccine second dose Seroconversion serology Sex significantly lower systemic therapy Type Vaccine vaccine dose virus were excluded [DOI] 10.1093/rheumatology/keab773 PMC 바로가기 [Article Type] Clinical Trial
A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated miceOmicron RBD 백신의 네 번째 용량은 백신 접종된 마우스에서 BA.1 및 BA.2를 포함한 SARS-CoV-2 변이체에 대한 광범위한 중화를 향상시킵니다.Article Published on 2022-08-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Antibody Response booster build COVID-19 pandemic cross-reactive demonstrated dose elicited ENhance escaped evaluated immunization induce mice NAb NAbs neutralization Neutralizing activity Neutralizing antibodies neutralizing antibody omicron Omicron variant RBD RBD vaccine SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV-2 variant SARS-CoV-2 variants sequential immunization. strain triggered Vaccine Vaccines variant was used [DOI] 10.1002/jmv.27811 PMC 바로가기 [Article Type] Article
Preliminary results on transmission of SARS-CoV-2 antibodies to the fetus and serum neutralizing activitySARS-CoV-2 항체의 태아로의 전파 및 혈청 중화 활성에 대한 예비 결과Article Published on 2022-08-012022-09-12 Journal: International journal of gynaecology and obstetric [Category] COVID19(2023년), SARS, 진단, [키워드] antibody during pregnancy fetus Immunity immunization Neutralizing activity Pregnancy SARS-CoV-2 SARS-CoV-2 antibodies SARS‐CoV‐2 serum serum neutralizing activity. transmission of SARS-CoV-2 [DOI] 10.1002/ijgo.14185 PMC 바로가기 [Article Type] Article
Generation and characterization of humanized synergistic neutralizing antibodies against SARS-CoV-2SARS-CoV-2에 대한 인간화 시너지 중화 항체의 생성 및 특성화Article Published on 2022-08-012022-09-12 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome antibody binding chimeric clinical therapy Combination coronavirus coronavirus disease COVID-19 epitope exhibited Generation global public health humanized humanized antibodies humanized neutralizing antibody Local neutralization activity Neutralizing Neutralizing activity neutralizing antibody Protein pseudovirus pseudovirus system RBD recognize SARS-CoV-2 SARS-CoV-2 pseudovirus single-chain antibody synergistic synergistic neutralizing activity. the receptor-binding domain the SARS-CoV-2 [DOI] 10.1002/jmv.27801 PMC 바로가기 [Article Type] Article
Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodiesArticle Published on 2022-08-012022-11-15 Journal: Journal of Clinical Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] affected analyzed auto-antibody autoantibodies benefit Biomarker circulating Clinical outcome clinical parameter clinically Cohort COVID-19 COVID-19 patient Critical Critically ill critically ill patients defined detectable disease Effect ELISA evaluated FIVE hospital Hospital admission hospitalized COVID-19 patient identification IFN-α interferon male Neutralization assay Neutralizing Neutralizing activity Oxygen requirement Patient post-symptom onset Prevalence probability of survival Rapid reduced SARS-CoV-2 SARS-CoV-2 antibody sera severe COVID-19 specificity subsequent survival Therapeutic plasma exchange Therapies TPE Type type I interferon undetectable uninfected control WHO [DOI] 10.1007/s10875-022-01252-2 PMC 바로가기
A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse seraVFLIP-X 스파이크를 생성하는 원형 mRNA 백신 프로토타입은 마우스 혈청에 의한 SARS-CoV-2 변이체의 광범위한 중화를 제공합니다Article Published on 2022-08-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] addition Amino acid amino acid sequence amino acids Antibody titers B.1.1.529 B.1.617.2 balance BNT162b2 boost cellular immune responses cleavage site COVID-19 vaccine Critical D614G detectable Disulfide disulfide bond E484K Evolution of SARS-CoV-2 FIVE flexible glycosylation greater humoral Humoral and cellular immune responses immune responses immunization immunized induce K417N L452R linear linker mice mRNA mRNA vaccine mRNA vaccines mRNA-1273 N501Y neutralization Neutralizing activity Neutralizing antibody response Neutralizing antibody titer neutralizing antibody titers offer pre-fusion producing proline proline substitutions prolines reduced response S-2P SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus sequence sera shown spike Spike protein spike trimer stability suggested T478K the spike protein transcript trimer trimeric Vaccine Vaccines variant variants variants of concern variants of interest VFLIP virus VOCs VOIs wildtype [DOI] 10.1016/j.antiviral.2022.105370 PMC 바로가기 [Article Type] Article